New York, Feb 8, 2026, 06:42 EST — Market closed
Kenvue Inc edged up 0.3% Friday, ending at $18.13. Shares moved in a tight band, flickering between $18.01 and $18.18. Volume hit roughly 63.5 million. With markets closed on Sunday, KVUE heads into the week hovering near that familiar $18 level.
This isn’t your average quiet session. Kimberly-Clark is snapping up Kenvue, the Tylenol manufacturer, for $3.50 in cash per share and tossing in 0.15 Kimberly-Clark shares for each Kenvue share. That’s flipped KVUE into a deal-spread name, not just a consumer health play. TD Cowen’s Robert Moskow flagged the Tylenol lawsuit risk as “hard to quantify.” Reuters
Kenvue plans to publish its fourth-quarter and full-year 2025 financials after the bell on Feb. 17. The company won’t hold its routine quarterly conference call, citing the pending transaction.
The board declared a quarterly dividend of $0.2075 a share, with payment set for Feb. 25. Shareholders on record by Feb. 11 will get the payout.
According to preliminary counts, around 96% of shares represented at Kimberly-Clark’s special meeting voted in favor of the share issuance for the acquisition. At Kenvue, the company said roughly 99% of the votes cast supported the merger agreement—this equates to about 77% of all outstanding Kenvue shares. Kimberly-Clark CEO Mike Hsu said, “We are grateful” for the strong backing. Kenvue CEO Kirk Perry pointed to the deal’s potential to “accelerate innovation” as both sides target a closing in the second half of 2026, pending regulatory clearance. Kenvue Investors
Based on Kimberly-Clark’s most recent price of $104.33, their cash-and-stock offer values each Kenvue share at about $19.15. With KVUE finishing the day at $18.13, that leaves a difference of around $1—basically, the market’s bet on timing, interest rates, and whether the deal might stall or fall apart.
The spread didn’t budge, despite U.S. stocks shooting higher on Friday. The S&P 500 tacked on 2%, Nasdaq up 2.2%, according to AP.
Traders now watch to see if Kenvue manages to hold margins and volumes intact during the run-up to the merger. If the Feb. 17 numbers are in line, KVUE could move nearer to its implied value. A miss, though, risks widening the gap.
The discount could widen fast if regulators drag out the process, or if a sudden twist in litigation changes the outlook. This week, a New Jersey appeals court tossed a plaintiffs’ firm from the state’s talc suits against Johnson & Johnson, citing an ethics violation. It’s a reminder: procedural curveballs can shift the landscape overnight in these drawn-out product cases.
